

Clinical trials of cerivastatin

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
cerivastatin vs placebo			
Laufs , 2004 n=8/7 follow-up: mean 20 weeks	cerivastatin 0.4 mg versus placebo	patients with heart failure NYHA II-III caused by non-ischemic dilated cardiomyopathy	Parallel groups double blind

More details and results :

- cholesterol lowering intervention for cardiovascular prevention in all chronic situations at <http://www.trialresultscenter.org/go-Q154>

References

Laufs, 2004:

Laufs U, Wassmann S, Schackmann S, Heeschen C, Bhm M, Nickenig G Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 2004;93:103-8 [14963675]

2 heart failure

Trial	Treatments	Patients	Trials design and methods
cerivastatin vs placebo			
Laufs , 2004 n=8/7 follow-up: mean 20 weeks	cerivastatin 0.4 mg versus placebo	patients with heart failure NYHA II-III caused by non-ischemic dilated cardiomyopathy	Parallel groups double blind

More details and results :

- cholesterol lowering intervention for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q176>
- statins for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q696>

References

Laufs, 2004:

Laufs U, Wassmann S, Schackmann S, Heeschen C, Bhm M, Nickenig G Beneficial effects of statins in patients with non-ischemic heart failure. *Z Kardiol* 2004;93:103-8
[14963675]

Entry terms: Baycol, Lipobay